Retrophin soars on its latest rare disease play

Damian Garde

, the biotech helmed by hedge funder Martin Shkreli, leapt more than 25% after buying the rights to another drug with the potential to treat a .

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS